On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act into law, also known as the “CARES Act”. The CARES Act is a wide ranging stimulus bill in response to the COVID-19 outbreak. Title I of the CARES Act (“Keeping American Workers Paid and Employed Act”) provides for the expansion of the Small Business Act (SBA) in order to create a new line of federally-guaranteed small business loans (“Program Loans”) available for the period of February 15, 2020 to June 30, 2020. These Program Loans are available to small businesses with fewer than 500 employees (see below for more detailed information) and permit such qualified small businesses to borrow up to 2.5 times the average total monthly payroll costs incurred in the one-year period before the Program Loan is made with a cap of $10 million. Program Loans do not require any collateral, have a deferred payment period of six months to one year and are eligible for loan forgiveness for certain categories of spending during the eight-week period following the issuance of the loan. View CARES Act summary
Join us to learn about the CARES Act and find out how your organization can get support. Q&A welcome.
To ensure a successful sale of your startup you need to start planning early. Several issues are key. Among them: how to maximize value; how to manage stakeholders; and how to close the deal, which is everything once you decide to sell. To learn how to do it right—as well as hard-learned lessons about what happens if you don’t—join us on Thursday, February 20 to hear from Sam Williams, a partner in corporate law at the firm Brown Rudnick.
Tak joined NEA in 2018 as a Principal on the healthcare team. He focuses on medical device investments.
Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).
Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.
This will be an interactive conversation between Dr. Eadie and Christine Winoto, Director and Founder of the UCSF Rosenman Institute. When you register, please let us know what questions you would most like answered.
This will be an interactive conversation between Neil and Christine Winoto, Director and Founder of the UCSF Rosenman Institute. When you register, please let us know what questions you would most like answered.
Investors and strategic partners want to understand your intellectual property so they can assess your chances of advancing your technology in the market. How well-developed does your IP position need to be before you can open discussions? Exactly how much should you reveal? And what do you do when your IP is not patentable? Get the answers Tuesday, September 24 from Adam Schoen, Partner at the law firm Brown Rudnick.
Meeting endpoints in a successful clinical trial ensures that the FDA will approve a medical device, right? As it turns out, there’s more to the picture. Tony Fields was VP of R&D at Emphasys and COO at Claret Medical, and in his career he saw FDA deny approval for an Emphasys device that met all primary and secondary endpoints in a trial–but, conversely, approve a Claret device that failed to meet its endpoints. How can this be? What other factors might matter to FDA? Join us Thursday, September 12 to find out.
Early-stage companies will have to obtain funding or go through an exit process at some point in time. Since intellectual property (IP) often represents the bulk of an early stage company’s assets, investors will typically conduct due diligence on the IP during their evaluation process. Key areas that are evaluated include ownership of the IP, strength of the company’s IP, and freedom-to-operate. Join us May 30 to get a primer on how to prepare for IP due diligence from Douglas Portnow and Piers Blewett from the IP law firm Schwegman Lundberg & Woessner.
This is the first in a series of events in which we bring clinicians and medical device engineers to discover unmet needs in a specialized area of medicine. In this event physicians will describe how they treat conditions, some of the challenges they face in delivering quality medical care, and possible solutions; engineers will discuss what is feasible and suggest alternative approaches. Join us for an intensely interactive session focused on pulmonary and critical care medicine.
Set yourself up for success in your startup’s approach to effectively navigate the regulatory pathway to market and maximize your interactions with FDA. Join this seminar to hear from Nada Hanafi, Chief Strategy Officer of Experien Group, headquartered in San Jose, CA. This discussion will focus on the critical success factors that go into a comprehensive regulatory strategy and the benefits of FDA’s Q-Submission process for state-of-the-art medical devices and innovative technologies.
